Insulin · Glucose · Clinical Decision Support

Diabetes is heterogeneous.
We measure why.

The first at-home rapid fingerstick test for insulin and glucose, paired with a clinical decision support system for metabolic phenotyping.

38M
Americans with Type 2 diabetes
Zero
at-home insulin tests exist
Guessing
Physicians are guessing on therapy
The Insight

The market is measuring
the wrong thing.

One hormone. Five phenotypes.

Glucose tells you that diabetes exists. Insulin tells you why. The same HbA1c can reflect five completely different metabolic phenotypes — each requiring a different clinical response. Without insulin data, physicians are guessing.

P1
Beta-Cell Dysfunction
P2
Incretin Impairment
P3
Hepatic Insulin Resistance
P4
Muscular Insulin Resistance
P5
Clearance Defect
The Product

A test, a decision engine, a workflow

From a single drop of blood to a clinical decision — inside the care infrastructure physicians already use.

Fingerstick Strip

Insulin + glucose from ~20 µL whole blood. No wearable. No lab. No specialty equipment.

CDSS

Classifies each patient into a metabolic phenotype. Generates actionable guidance per result.

RPM Integration

Fits into existing Remote Patient Monitoring workflows. No new billing infrastructure required.

Validated Performance
0.96 pM
Limit of Detection
98–99%
Spike Recovery
R² 0.999
Linearity vs. ELISA
94%
Signal Stability

Interested in the
technology?

We're working with clinicians, researchers, and industry partners.

Connect on LinkedIn